2013-2014 top 100 best selling drugs in the United States

Source: on May 14, 2014, in the list of top 100 prescriptions and sales volume in the United States recently released by DXY, hypothyroid drugs and L-thyroid (Albright) continue to occupy the top of the list of prescription volume in the United States every month, while antipsychotic drug abilifly (Otsuka pharmaceutical) leads the list of drug sales volume in the United States According to the latest statistics of Ames Research Company, the current sales volume of the drug is 6.9 billion US dollars These data clearly reflect the ups and downs of total drug sales and prescriptions in the United States during the ups and downs of the year from April 2013 to March 2014 It can be seen that levothyroxine leads the list with 23 million prescriptions, followed by cholesterol lowering drug Crestor (AstraZeneca), which also has an astonishing 22.9 million prescriptions; proton pump inhibitor esomeprazole (patience, AstraZeneca) ranks third with 19.3 million prescriptions The asthma drug Ventolin HFA (GSK) was kept at 17.5 million; the chronic obstructive pulmonary disease treatment drug fluticasone / salmeterol (advair Diskus, GSK) also had a good performance, and its prescription amount exceeded 15.5 million After the top 10, the antidepressant Cymbalta, the antihypertensive Valsartan Dispersible Tablets (Diovan, Novartis), the attention deficit disorder drug vyvanse, glargine insulin (Lantus SoloSTAR, Sanofi), and the epilepsy drug Lyrica , Pfizer pharmaceutical), next On the other hand, on the list of sales volume, those who are closely related to aripiprazole (Otsuka pharmaceutical) are esomeprazole (Nexium, AstraZeneca) with sales volume of 6.3 billion US dollars, and adamumumab (Humira, Alberta), an anti arthritis drug with sales volume of 5.9 billion US dollars Top 10 top selling drugs include Crestor (5.5 billion), Adair Diskus (5.1 billion), embrel (4.9 billion), REMICADE (4.2 billion), Cymbalta (4.1 billion), Copaxone (Teva Pharm; nearly 37 Neulasta (amjin, US $3.6 billion) For more details, please refer to: http://yao.dxy.cn/article/75416